451 related articles for article (PubMed ID: 30283014)
1. Chronic lymphocytic leukemia treatment algorithm 2018.
Parikh SA
Blood Cancer J; 2018 Oct; 8(10):93. PubMed ID: 30283014
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia treatment algorithm 2022.
Hampel PJ; Parikh SA
Blood Cancer J; 2022 Nov; 12(11):161. PubMed ID: 36446777
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
Iovino L; Shadman M
Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
6. Current Treatment of Chronic Lymphocytic Leukemia.
Jamroziak K; Puła B; Walewski J
Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
[TBL] [Abstract][Full Text] [Related]
7. [Chronic lymphocytic leukemia: pathophysiology and current therapy].
Takizawa J
Rinsho Ketsueki; 2017; 58(5):471-479. PubMed ID: 28592762
[TBL] [Abstract][Full Text] [Related]
8. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
9. Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era.
Brander D; Islam P; Barrientos JC
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():487-498. PubMed ID: 31099686
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
11. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
[TBL] [Abstract][Full Text] [Related]
12. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.
Innocenti I; Autore F; Pasquale R; Morelli F; Efremov DG; Laurenti L
Expert Rev Hematol; 2017 Dec; 10(12):1069-1076. PubMed ID: 29082795
[TBL] [Abstract][Full Text] [Related]
13. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
14. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
Zelenetz AD; Gordon LI; Wierda WG; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Czuczman MS; Fayad LE; Fisher RI; Glenn MJ; Habermann TM; Harris NL; Hoppe RT; Horwitz SM; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Nademanee A; Porcu P; Press O; Rabinovitch R; Reddy N; Reid E; Saad AA; Sokol L; Swinnen LJ; Tsien C; Vose JM; Wilson L; Yahalom J; Zafar N; Dwyer M; Sundar H;
J Natl Compr Canc Netw; 2015 Mar; 13(3):326-62. PubMed ID: 25736010
[TBL] [Abstract][Full Text] [Related]
15. Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Mato AR; Wierda WG; Davids MS; Cheson BD; Coutre SE; Choi M; Furman RR; Heffner L; Barr PM; Eradat H; Ford SM; Zhou L; Verdugo M; Humerickhouse RA; Potluri J; Byrd JC
Haematologica; 2019 Nov; 104(11):2258-2264. PubMed ID: 30923097
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
17. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
Wendtner CM; Gregor M
Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
20. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
